News

Don’t let these common misconceptions stop you from this high-impact, low-cost way to engage with patients.

Type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, according to FDA’s new Drug Safety Communication.

Telemedicine could improve diabetic patient outcomes, expand access, and provide better economic value for patients. Find out how.

Soon after FDA expanded access to the “abortion pill” or mifepristone (Mifeprex, Danco Laboratories), some states may be combating the decision.

A recent Supreme Court decision shines the spotlight on the healthcare price transparency debate.

FDA recently approved reslizumab (Cinqair, Teva Pharmaceuticals), an injectable used with other asthma medicines for the maintenance treatment of severe asthma. Here are the top 5 facts to know about Cinqair.

Consequences range from cardiovascular disease to renal disease

The approaches reflect a growing number of initiatives meant to tie drug prices to value. Find out more.

Here are some of the innovative approaches payers and providers are taking to quell the diabetes epidemic, and curb the costs associated with it.

As patients look to make more informed decisions about healthcare services, payers can leverage comparative analytics to deliver greater price transparency

There is so much data available at all levels of healthcare, and technology and public support is on the cusp of a breakthrough in using this information for widespread improvements.

FDA recently approved the first generic version of Nasonex nasal spray (mometasone furoate monohydrate, Apotex Corp).

Here are three questions payers must ask to determine providers’ readiness to engage in risk-based reimbursement.

A successful YMCA diabetes program has prompted the Obama administration to expand Medicare to cover programs to prevent diabetes among those at high risk of developing the disease.

Diabetes prevention program found to improve quality and reduces healthcare costs. It will now be covered by Medicare in 2017.

The sheer volume of diabetes patients has made it a big driver of medication spending. Here are some important formulary considerations.

FDA recently approved antihemophilic factor VIII (recombinant) (Kovaltry, Bayer) for the treatment of hemophilia A in children and adults.

FDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

State and federal regulations, health information breaches, create a minefield of issues

Industry insiders believe that the Anthem lawsuit against Express Scripts over drug pricing may provide some clues into this complex situation.

Concerns among stakeholders may call for EHR system revamping

An in-depth look at the effects of PDMPs, which are electronic databases used to track the prescribing and dispensing of controlled prescription drugs to patients.

FDA this week approved obiltoxaximab injection, (Anthim, Elusys Therapeutics), to treat inhalational anthrax.

FDA issued a draft guidance to support industry in their development of generic versions of approved opioids with abuse-deterrent formulations (ADF), while ensuring that generic ADF opioids are no less abuse-deterrent than the brand-name drug.

… and solutions from experts

While value-based reimbursement presents opportunities for payers and providers, succeeding in such a reimbursement model can be challenging. Here are four things to strive for that could increase the likelihood of success in a value-based reimbursement model.

While the high cost of specialty pharmacy is no surprise in the healthcare industry, infusibles have additional challenges. Here are the challenges that top the list, and what to do about them.

Find out what causes human error in a healthcare setting, and how to prevent it.

FDA has extended approval of crizotinib (Xalkori, Pfizer) for the treatment of certain patients with non-small cell lung cancer (NSCLC).

In the move to value-based care, there have been surprises and disruptions for payers and providers alike. In this Q&A, an expert shares where we are now.